Recombinant-Methionyl Human Stem Cell Factor
Sickle Cell-Hemoglobin C Disease Syndrome
Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00005783CT.gov A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell-Hemoglobin C Disease Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant-Methionyl Human Stem Cell Factor (this asset) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P1 | CC · 47 |
| Hydroxyurea | Nova Laboratories Limited | P2 | BB |
| mp4co | Sangart | P2 | B |
| Busulfanum | Tami D. John | P2 | CCC |
| Prednisone | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | CCC |
| Fludarabine | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Tacrolimus | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Magnesium Pidolate | St. Jude Children's Research Hospital | P2 | CCC |
| Tovinontrine | Cardurion Pharmaceuticals, Inc. | P1 | CC |
+6 more in the Sickle Cell-Hemoglobin C Disease Syndrome cohort
Other indications for Recombinant-Methionyl Human Stem Cell Factor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant-Methionyl Human Stem Cell Factor in Sickle Cell-Hemoglobin C Disease Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-methionyl-human-stem-cell-factor-sickle-cell-hemoglobin-c-disease-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →